ClinicalTrials.gg
CompletedNCT02190747Updated Feb 16, 2021Results posted

An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects

A Phase 2 interventional study of Palovarotene and Placebo in Fibrodysplasia Ossificans Progressiva, sponsored by Clementia Pharmaceuticals Inc.. Completed at 4 sites in 3 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2021-02-16.

Sponsored by Clementia Pharmaceuticals Inc. (part of Ipsen) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Myositis Ossificans by Ipsen — 1 open to participants now, 1 under way, none of them phase 3. Myositis Ossificans · Ipsen.

Started
2014
with 2 others
Phase 2
4 of 10
none open now
Registered
1st of 10
by date

Among the 10 studies in Myositis Ossificans by Ipsen, this one is one of 3 that started in 2014, is one of 4 in phase 2, and was the 1st registered.

Myositis Ossificans

24 studies on the registry are indexed under Myositis Ossificans; 5 are open to participants now.

Browse Myositis Ossificans studies →

Open to participants now

1 of the 10 studies in Myositis Ossificans by Ipsen is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 4 Myositis Ossificans studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Myositis Ossificans by Ipsen, or all of them as a file.
02

Study summary

Fibrodysplasia ossificans progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in abnormal bone formation in muscles, tendons, and ligaments. Flare-ups begin early in life and may occur spontaneously or after soft tissue trauma, vaccinations, or influenza infections. Recurrent flare-ups progressively restrict movement by locking joints leading to cumulative loss of function and disability. Mouse models of FOP have demonstrated the ability of retinoic acid receptor (RAR) gamma agonists to prevent heterotopic ossification (HO) following injury. The purpose of the study is to evaluate whether palovarotene, an RAR gamma agonist, will prevent HO during and following a flare-up in subjects with FOP.

Read the detailed description

The primary objective is to evaluate the ability of different doses of palovarotene to prevent HO at the flare-up site in subjects with FOP as assessed by plain radiographs.

This is a Phase 2, multi-center, randomized, double-blind, sponsor-unblinded, placebo-controlled study. Two cohorts of subjects will be randomized into different dosing regimens of palovarotene for a 6-week (42 days) treatment period. The study will consist of three periods:

  1. A Screening period to occur within 7 days of a distinct flare-up. The first dose of study drug will be taken within 7 days of the flare-up initiation.
  2. A double-blind treatment period of 6 weeks (42 days) duration.
  3. A follow-up period of 6 weeks (42 days) duration.

An initial cohort (Cohort 1) of subjects will be randomly assigned 3:1 to either palovarotene or placebo daily for 42 days. Subjects randomized to palovarotene in Cohort 1 will receive an initial daily dose of 10 mg for 14 days followed by 5 mg daily for 28 days.

In Cohort 2, new FOP subjects meeting all inclusion/exclusion criteria will be randomly assigned 3:3:2 to two dose regimens of palovarotene (10 mg for 14 days and 5 mg for 28 days; 5 mg for 14 days and 2.5 mg for 28 days) or placebo daily for 42 days. Doses will be weight-adjusted and subjects randomized within three weight-range categories (20 to \<40 kg, 40 to \<60 kg, and ≥60 kg).

Subjects completing the study and still meeting eligibility requirements will be given the opportunity to enroll into an open-label extension study.

03

Conditions studied

  • Fibrodysplasia Ossificans Progressiva

Keywords

  • Intervention study
  • Clinical trial Phase 2
  • Efficacy and safety
  • Heterotopic ossification
  • Flare-up
  • Palovarotene
  • Retinoic acid receptor agonist
  • Retinoic acid receptor gamma agonist
  • Clementia
  • Myositis Ossificans Progressiva
  • Munchmeyer's Disease
  • FOP
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written, signed, and dated informed subject/parent consent or age-appropriate assent.
  • Subjects clinically diagnosed with classic Fibrodysplasia Ossificans Progressiva (FOP).
  • Symptomatic onset of a distinct flare-up within 7 days of Study Day 1 (start of study drug) and defined by the presence of at least two of six of the following symptoms: pain, soft tissue swelling, decreased range of motion, stiffness, redness, and warmth. Flare-up must be confirmed by the physician at the Screening visit.
  • Flare-up is at an appendicular area (upper or lower extremity), abdomen, or chest; and subject has received, is receiving, or is willing to receive treatment per standard of care, which may or may not include oral prednisone (2 mg/kg PO to a maximum dose of 100 mg daily) for 4 days.
  • Abstinent or using two highly effective forms of .
  • Subjects must be accessible for treatment and follow-up. Subjects living at distant locations from the site must be able and willing to travel to a site for the initial and all follow-up visits.

Exclusion criteria

Exclusion Criteria:

  • Weight \<20 kg.
  • Intercurrent non-healed fracture at any location.
  • Complete immobilization of joint at site of flare-up.
  • The inability of the subject to undergo imaging assessments using plain radiographs.
  • If currently using vitamin A or beta carotene, multivitamins containing vitamin A or beta carotene, or herbal preparations, fish oil, and unable or unwilling to discontinue use of these products for the duration of the study.
  • Exposure to synthetic oral retinoids in the past 30 days prior to Screening (signature of the ).
  • Concurrent treatment with tetracycline due to the potential increased risk of pseudotumor cerebri.
  • History of allergy or to retinoids or lactose.
  • Concomitant medications that are inhibitors or inducers of CYP450 3A4 activity.
  • Amylase or lipase >1.5x above the or with a history of chronic pancreatitis.
  • Elevated or alanine aminotransferase >2.5x the upper limit of normal.
  • Fasting triglycerides >400 mg/dL with or without therapy.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Palovarotene dose level 1 (Cohort 1)

    Doses of palovarotene in dose level 1 are 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days.

    Drug: Palovarotene

  • Experimental
    Palovarotene dose level 2 (Cohort 2)

    Weight-adjusted doses of palovarotene in dose level 2 are 10 mg palovarotene once daily, followed by 5 mg once daily for 28 days.

    Drug: Palovarotene

  • Experimental
    Palovarotene dose level 3 (Cohort 2)

    Weight-adjusted doses of palovarotene in dose level 3 are 5 mg palovarotene once daily, followed by 2.5 mg once daily for 28 days.

    Drug: Palovarotene

  • Placebo comparator
    Sugar pill

    The placebo comparator will be taken once daily for the same duration as the palovarotene dose groups in both Cohorts 1 and 2.

    Drug: Placebo

Interventions

  • Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Percentage of Responders at Week 6

    A responder was defined as a subject with no or minimal new heterotopic ossification (HO) at flare-up site versus baseline as assessed by plain radiographs at Week 6. Minimal new HO is defined as new HO with an HO score \<=3 in both anterior/posterior (AP) and lateral projections (or if one view is non-interpretable or non-evaluable, then remaining evaluable view is used). The HO score ranges from 0 to 6 where, 0 = no HO and 6 = single contiguous HO with longest dimension \>2 diameters of reference normotopic bone in any projection. The highest HO score from the 2 projections was used. Results from Primary Read reviews are presented. The Primary Read process included a double-read radiology review paradigm with consensus adjudication. Radiography and CT scans were examined independently by scan type, flare-up region, and imaging time point in order to determine whether radiography would be sufficient to measure new HO formation. Only subjects with interpretable outcomes were evaluated.

    Time frame: Baseline (Day 1) and Week 6 (Day 42)

Secondary outcomes

  1. Percentage of Subjects With New HO at Weeks 6 and 12

    Low dose CT scan was used as a secondary imaging assessment of HO and was performed at the same time points as plain radiographs. The percentage of subjects with new HO (regardless of the amount of new HO) at the flare-up site as assessed by CT scan and/or plain radiographs at Weeks 6 and 12 were analysed. The results are from Global Read reviews. The holistic Global Read process allowed concurrent review of all modalities across all time points, and provided access to selected clinical data at the time of review.

    Time frame: Weeks 6 and 12 (Day 84)

  2. Change From Baseline in Amount (Area) of New HO Formed at the Flare-up Site at Weeks 6 and 12

    Interpretation of plain radiographs document the amount (area) of HO on both the AP and lateral radiograph views. The area for each view was a sum of all the new HO at the flare-up location (and thus if there are multiple HO lesions, the area of each lesion was determined and then the total across all lesions were summed to obtain a total new HO). This total new HO sum was used in the analysis of the area of new HO. Results from Primary Read reviews are presented.

    Time frame: Baseline, Weeks 6 and 12

  3. Percentage of Responders at Week 12

    A responder was defined as a subject with no or minimal new HO at the flare-up site versus baseline as assessed by plain radiographs at Week 12. Minimal new HO is defined as new HO with an HO score \<=3 in both the AP and lateral projections (or if one view is non-interpretable or non-evaluable, then the remaining evaluable view is used). The HO score ranges from 0 to 6 where, 0 = no HO and 6 = single contiguous HO with longest dimension \>2 diameters of the reference normotopic bone in any projection. The highest HO score from the 2 projections was used. Results from the Primary Read reviews are presented. The Primary Read process included a double-read radiology review paradigm with consensus adjudication. Radiography and CT scans were examined independently by scan type, flare-up region, and imaging time point in order to determine whether radiography would be sufficient to measure new HO formation.

    Time frame: Baseline and Week 12

  4. Change From Baseline in Bone Specific Alkaline Phosphatase at Weeks 2, 4, 6 and 12

    Blood and urine samples for analysis of cartilage, bone, angiogenesis, and inflammation biomarkers were collected. Bone specific alkaline phosphatase was analysed as a bone and cartilage biomarker.

    Time frame: Baseline, Weeks 2, 4, 6 and 12

  5. Change From Baseline in C-Reactive Protein at Weeks 2, 4, 6 and 12

    Blood and urine samples for analysis of cartilage, bone, angiogenesis, and inflammation biomarkers were collected. C-reactive protein was analysed as a inflammation biomarker.

    Time frame: Baseline, Weeks 2, 4, 6 and 12

  6. Change From Baseline in C-Terminal Telopeptide at Weeks 2, 4, 6 and 12

    Blood and urine samples for analysis of cartilage, bone, angiogenesis, and inflammation biomarkers were collected. C-terminal telopeptide was analysed as a bone and cartilage biomarker.

    Time frame: Baseline, Weeks 2, 4, 6 and 12

  7. Change From Baseline in Procollagen Type 1 N-Terminal Propeptide at Weeks 2, 4, 6 and 12

    Blood and urine samples for analysis of cartilage, bone, angiogenesis, and inflammation biomarkers were collected. Procollagen type 1 N-terminal propeptide was analysed as a bone and cartilage biomarker.

    Time frame: Baseline, Weeks 2, 4, 6 and 12

  8. Change From Baseline in Procollagen Type 1 C-Terminal Propeptide Biomarker at Weeks 2, 4, 6 and 12

    Blood and urine samples for analysis of cartilage, bone, angiogenesis, and inflammation biomarkers were collected. Procollagen type 1 C-terminal propeptide was analysed as a bone and cartilage biomarker.

    Time frame: Baseline, Weeks 2, 4, 6 and 12

  9. Change From Baseline in Amount of Bone Formation (Volume) at Weeks 6 and 12

    Low dose CT scan were used as a secondary imaging assessment of HO, and was performed at the same time points as plain radiographs. Interpretation of the CT scan documented the amount (volume) and grade of HO. The independent reviewer scored HO lesions according to the following scale for HO on CT. Grade 1 = fluid attenuation without evidence of calcification at CT, Grade 2 = calcification of soft tissues without evidence of bone formation, Grade 3 = immature bone formation, and Grade 4 = mature bone with cortical differentiation. Volume of new HO was determined according to the following steps: (1) calculate volume of new HO compared to baseline for each reviewer/HO ID, (2) sum the volume of new HO across HO IDs for each reviewer, and (3) average the volume of new HO across reviewers. Results from Primary Read reviews are presented.

    Time frame: Baseline, Weeks 6 and 12

  10. Percentage of Subjects With Soft Tissue Swelling and Cartilage Formation Assessed by Magnetic Resonance Imaging (MRI) or Ultrasound (US) at Weeks 6 and 12

    The MRI was utilized to evaluate the presence of soft tissue swelling/edema (and volume of the swelling/edema) and presence of cartilage formation (yes or no). For subjects who could not have an MRI, US was used to assess edema severity for the sub-set of subjects enrolled after this opinion was introduced in a protocol amendment. Imaging film from MRI was assessed by two independent readers. When there was sufficient agreement between the independent readers on volume, both of the independent readings were used for analysis with the volume measurements averaged. When there was insufficient agreement between the independent readers, an adjudication reading was provided and used for analysis. The US was used for soft tissue swelling/edema but not cartilage formation. Percentage calculated as % = 100 x n/N' where N' is the number of subjects with interpretable outcomes. Results from Primary Read reviews are presented.

    Time frame: Weeks 6 and 12

  11. Change From Baseline in Percent of Normal Arc of Motion at the Primary Joint (Flare-up Site) at Weeks 6 and 12

    Active range of motion, expressed as the percent of normal arc of motion, measurements at the primary joint associated with the flare-up and adjoining joints was assessed by goniometer.

    Time frame: Baseline, Weeks 6 and 12

  12. Subject and Investigator Global Assessment of Movement at Weeks 6 and 12

    Flare-up movement outcomes were independently assessed by both the subject (or parent of a subject under 8 years of age) and the Investigator at Weeks 6 and 12 by completing the global assessment of movement. The subject/parent completed the global assessment first. Prior to reviewing the subject's assessment, the Investigator completed his/her own assessment of the flare-up outcome. Subjects were assessed how the flare-up affected their movement on a scale ranging 1 to 5 where, 1 = severely worse movement and 5 = better movement compared with study Day 1 (day of first dose of study drug). Investigators were assessed how the flare-up affected the subject's movement on a scale ranging 1 to 5 where, 1 = severely worse movement and 5 = better movement compared with baseline (day of screening physical examination).

    Time frame: Weeks 6 and 12

  13. Change From Baseline in Flare-Up Pain and Swelling at Weeks 2, 4, 6, 9 and 12

    The pain and swelling associated with flare-ups was evaluated using 2 separate numeric rating scales, one for pain and one for swelling. The pain scale ranges from 0 to 10 where, 0 = no pain and 10 = worst pain ever experienced. The swelling scale ranges from 0 to 10 where, 0 = no swelling and 10 = worst swelling ever experienced. The Faces Pain Scale - Revised (FPS-R) was used for children less than 8 years old. The FPS-R ranges from 0 to 10 where, 0 = no pain and 10 = very much pain in two-point increments.

    Time frame: Baseline, Weeks 2, 4, 6, 9 and 12

  14. Percentage of Subjects Who Used Any Assistive Devices and Adaptations for Daily Living at Weeks 6 and 12

    Subjects were given a list of FOP assistive devices and adaptations and asked to select those they use for daily living. The FOP assistive devices and adaptations included mobility aids, care attendants, eating tools, personal care tools/aids, bathroom aids and devices, bedroom aids and devices, home adaptations, work environment adaptations, technology adaptations, sports and recreation adaptations, school, and medical therapies for daily living.

    Time frame: Weeks 6 and 12

  15. Duration of Active Symptomatic Flare-up

    The duration of active symptomatic flare-up was defined as the number of days the subject reported the presence of symptoms in the diary ('Is your flare-up ongoing today?') from Day 1 to study completion at Day 84. The mean number of days of active, symptomatic flare-up is presented for subjects with evaluable diary data.

    Time frame: From Day 1 to Day 84

  16. Change From Baseline in Percentage of Worst Total Score for FOP-Specific Physical Function Questionnaire (FOP-PFQ) at Weeks 2, 4, 6, 9 and 12

    The FOP-PFQ consists of 28 questions rated on scales from 1 to 5, with lower scores denoting more difficulty. The adult form of the FOP-PFQ was administered to subjects 15 years of age and older. There are two Pediatric FOP-PFQ (FOP-PFQ-P) forms: a self-completed form for 8 to 14 year-olds and a parent proxy-completed form for 5 to 14 year-olds. For subjects between 8 to 14 years of age, both the self-completed (for 8 to 14 year-olds) and the proxy-completed (for 5 to 14 year olds) forms of the FOP-PFQ-P were administered. However, only the proxy-completed form was used for analysis. Percentage of worst scores ranges from 0% to 100% with 0% = best possible function and 100% = worst possible function. Change from baseline for each time point is presented.

    Time frame: Baseline, Weeks 2, 4, 6, 9 and 12

  17. Change From Baseline in Physical and Mental Health Using Age-Appropriate Forms of the Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale at Weeks 2, 4, 6, 9 and 12

    The PROMIS Global Health contains 10 questions which are rated on scales from 1 to 5 or 0 to 10. Global physical health scores were calculated as the sum of scores from parameters 3, 6, 7, and 8 and ranges from 4 to 20 where, 4 = worse health and 20 = better health. Global mental health scores were calculated as the sum of scores from parameters 2, 4, 5, and 10 and ranges from 4 to 20 where, 4 = worse health and 20 = better health. For paediatric subjects, the PROMIS was administered as per the adult version. However, there is a single total score for the paediatric PROMIS (as opposed to global physical and global mental health scores as are in the adult version). The total score were converted to a T-score. A T-score of 50 is normal and increments of 10 are +/- 1 standard deviation away from the norm. A T-score \<50 indicates worse health, while a T-score \>50 indicates better health. The higher values (positive changes) indicate better health.

    Time frame: Baseline, Weeks 2, 4, 6, 9 and 12

  18. Maximum Measured Plasma Concentration (Cmax) of Palovarotene

    The Cmax of palovarotene was determined.

    Time frame: Pre-dose and 3, 6, 10, and 24 hours (hrs) post-dose at Week 2, and at Week 4 or 6

  19. Minimum Measured Plasma Concentration (Cmin) of Palovarotene

    The Cmin of palovarotene was determined.

    Time frame: Pre-dose and 3, 6, 10, and 24 hrs post-dose at Week 2, and at Week 4 or 6

  20. Time of Maximum Measured Plasma Concentration (Tmax) of Palovarotene

    The Tmax obtained by inspection of palovarotene was determined.

    Time frame: Pre-dose and 3, 6, 10, and 24 hrs post-dose at Week 2, and at Week 4 or 6

  21. Apparent Terminal Elimination Half-life (t1/2) of Palovarotene

    The t1/2 was calculated as ln(2)/ λz. The number of data points included in the regression was determined by visual inspection, but a minimum of three data points in the terminal phase, excluding Cmax, was required to estimate λz.

    Time frame: Pre-dose and 3, 6, 10, and 24 hrs post-dose at Week 2, and at Week 4 or 6

  22. Area Under the Plasma Concentration Versus Time Curve Over the 24-hr Dosing Interval (AUC[0-24hr]) of Palovarotene

    The AUC(0-24hr) was calculated using linear trapezoid rule.

    Time frame: Pre-dose and 3, 6, 10, and 24 hrs post-dose at Week 2, and at Week 4 or 6

  23. Apparent Clearance of Palovarotene (CL/F)

    The CL/F was defined as dose/AUC0-24hr.

    Time frame: Pre-dose and 3, 6, 10, and 24 hrs post-dose at Week 2, and at Week 4 or 6

07

Results

Posted Jun 24, 2020
Limitations and caveats
Radiography was less sensitive than CT for detecting new HO. Thus, Global Read data are presented where available using more sensitive CT scans at Week 12 in the PP population.

Participant flow

Eight subjects were randomized 3:1 to either palovarotene or placebo in Cohort 1; 8 additional subjects were randomized 3:1 in an interim period between Cohorts 1 and 2. In Cohort 2, 24 additional fibrodysplasia ossificans progressiva (FOP) subjects were randomized 3:3:2 across 2 weight-based regimens of palovarotene or placebo.

Participant flow — Overall Study
MilestonePalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Started21910
Completed21910
Not completed000

Outcome measures

PrimaryPercentage of Responders at Week 6

A responder was defined as a subject with no or minimal new heterotopic ossification (HO) at flare-up site versus baseline as assessed by plain radiographs at Week 6. Minimal new HO is defined as new HO with an HO score \<=3 in both anterior/posterior (AP) and lateral projections (or if one view is non-interpretable or non-evaluable, then remaining evaluable view is used). The HO score ranges from 0 to 6 where, 0 = no HO and 6 = single contiguous HO with longest dimension \>2 diameters of reference normotopic bone in any projection. The highest HO score from the 2 projections was used. Results from Primary Read reviews are presented. The Primary Read process included a double-read radiology review paradigm with consensus adjudication. Radiography and CT scans were examined independently by scan type, flare-up region, and imaging time point in order to determine whether radiography would be sufficient to measure new HO formation. Only subjects with interpretable outcomes were evaluated.

Time frame:
Baseline (Day 1) and Week 6 (Day 42)
Reported as:
Number · percentage of subjects
Percentage of Responders at Week 6
percentage of subjectsPalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Percentage of Responders at Week 610088.988.9
Statistical analysis
  • Palovarotene 10/5 mg vs Palovarotene 5/2.5 mg vs Placebo · Cochran-Armitage test of trend · p = 0.1664
SecondaryPercentage of Subjects With New HO at Weeks 6 and 12

Low dose CT scan was used as a secondary imaging assessment of HO and was performed at the same time points as plain radiographs. The percentage of subjects with new HO (regardless of the amount of new HO) at the flare-up site as assessed by CT scan and/or plain radiographs at Weeks 6 and 12 were analysed. The results are from Global Read reviews. The holistic Global Read process allowed concurrent review of all modalities across all time points, and provided access to selected clinical data at the time of review.

Time frame:
Weeks 6 and 12 (Day 84)
Reported as:
Number · percentage of subjects
Percentage of Subjects With New HO at Weeks 6 and 12
percentage of subjectsPalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Week 615.022.230.0
Week 1215.044.440.0
Statistical analysis
  • Palovarotene 10/5 mg vs Palovarotene 5/2.5 mg vs Placebo · Cochran-Armitage test of trend · p = 0.2335
  • Palovarotene 10/5 mg vs Palovarotene 5/2.5 mg vs Placebo · Cochran-Armitage test of trend · p = 0.0837
SecondaryChange From Baseline in Amount (Area) of New HO Formed at the Flare-up Site at Weeks 6 and 12

Interpretation of plain radiographs document the amount (area) of HO on both the AP and lateral radiograph views. The area for each view was a sum of all the new HO at the flare-up location (and thus if there are multiple HO lesions, the area of each lesion was determined and then the total across all lesions were summed to obtain a total new HO). This total new HO sum was used in the analysis of the area of new HO. Results from Primary Read reviews are presented.

Time frame:
Baseline, Weeks 6 and 12
Reported as:
Mean · square millimeters (mm)
Change From Baseline in Amount (Area) of New HO Formed at the Flare-up Site at Weeks 6 and 12
square millimeters (mm)Palovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Week 60.00 ± 0.00038.85 ± 116.54275.89 ± 176.744
Week 1219.00 ± 84.95571.22 ± 213.650621.71 ± 1287.519
Statistical analysis
  • Palovarotene 10/5 mg vs Placebo · Pairwise test · p = 0.6984 · Least square (ls) mean: -86.35
  • Palovarotene 5/2.5 mg vs Placebo · Pairwise test · p = 0.8811 · Ls mean: -38.07
  • Palovarotene 10/5 mg vs Placebo · Pairwise test · p = 0.0017 · Ls mean: -764.38
  • Palovarotene 5/2.5 mg vs Placebo · Pairwise test · p = 0.0094 · Ls mean: -703.43
SecondaryPercentage of Responders at Week 12

A responder was defined as a subject with no or minimal new HO at the flare-up site versus baseline as assessed by plain radiographs at Week 12. Minimal new HO is defined as new HO with an HO score \<=3 in both the AP and lateral projections (or if one view is non-interpretable or non-evaluable, then the remaining evaluable view is used). The HO score ranges from 0 to 6 where, 0 = no HO and 6 = single contiguous HO with longest dimension \>2 diameters of the reference normotopic bone in any projection. The highest HO score from the 2 projections was used. Results from the Primary Read reviews are presented. The Primary Read process included a double-read radiology review paradigm with consensus adjudication. Radiography and CT scans were examined independently by scan type, flare-up region, and imaging time point in order to determine whether radiography would be sufficient to measure new HO formation.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of subjects
Percentage of Responders at Week 12
percentage of subjectsPalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Percentage of Responders at Week 1295.088.977.8
Statistical analysis
  • Palovarotene 10/5 mg vs Palovarotene 5/2.5 mg vs Placebo · Cochran-Armitage test of trend · p = 0.1503
SecondaryChange From Baseline in Bone Specific Alkaline Phosphatase at Weeks 2, 4, 6 and 12

Blood and urine samples for analysis of cartilage, bone, angiogenesis, and inflammation biomarkers were collected. Bone specific alkaline phosphatase was analysed as a bone and cartilage biomarker.

Time frame:
Baseline, Weeks 2, 4, 6 and 12
Reported as:
Mean · microgram per liter (mcg/L)
Change From Baseline in Bone Specific Alkaline Phosphatase at Weeks 2, 4, 6 and 12
microgram per liter (mcg/L)Palovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Week 2-1.33 ± 13.267-3.18 ± 4.61912.02 ± 35.263
Week 4-1.41 ± 8.3283.80 ± 12.0727.53 ± 10.208
Week 6-2.53 ± 8.1570.74 ± 3.3166.23 ± 6.851
Week 122.49 ± 5.5060.89 ± 6.73810.00 ± 10.091
SecondaryChange From Baseline in C-Reactive Protein at Weeks 2, 4, 6 and 12

Blood and urine samples for analysis of cartilage, bone, angiogenesis, and inflammation biomarkers were collected. C-reactive protein was analysed as a inflammation biomarker.

Time frame:
Baseline, Weeks 2, 4, 6 and 12
Reported as:
Mean · mg/L
Change From Baseline in C-Reactive Protein at Weeks 2, 4, 6 and 12
mg/LPalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Week 28.62 ± 28.0850.09 ± 2.370-1.59 ± 1.909
Week 41.48 ± 4.92423.26 ± 38.3112.34 ± 3.704
Week 60.14 ± 3.4192.70 ± 7.9841.20 ± 1.319
Week 122.82 ± 11.7621.27 ± 1.789-0.30 ± 2.951
SecondaryChange From Baseline in C-Terminal Telopeptide at Weeks 2, 4, 6 and 12

Blood and urine samples for analysis of cartilage, bone, angiogenesis, and inflammation biomarkers were collected. C-terminal telopeptide was analysed as a bone and cartilage biomarker.

Time frame:
Baseline, Weeks 2, 4, 6 and 12
Reported as:
Mean · mcg/L
Change From Baseline in C-Terminal Telopeptide at Weeks 2, 4, 6 and 12
mcg/LPalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Week 2-0.020 ± 0.2900.118 ± 0.3590.071 ± 0.342
Week 40.015 ± 0.3370.095 ± 0.3800.188 ± 0.219
Week 60.105 ± 0.3040.078 ± 0.2930.125 ± 0.351
Week 120.116 ± 0.2410.054 ± 0.2850.126 ± 0.197
SecondaryChange From Baseline in Procollagen Type 1 N-Terminal Propeptide at Weeks 2, 4, 6 and 12

Blood and urine samples for analysis of cartilage, bone, angiogenesis, and inflammation biomarkers were collected. Procollagen type 1 N-terminal propeptide was analysed as a bone and cartilage biomarker.

Time frame:
Baseline, Weeks 2, 4, 6 and 12
Reported as:
Mean · mcg/L
Change From Baseline in Procollagen Type 1 N-Terminal Propeptide at Weeks 2, 4, 6 and 12
mcg/LPalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Week 253.022 ± 72.09178.930 ± 113.44342.058 ± 77.358
Week 4123.986 ± 207.513117.476 ± 169.238194.193 ± 318.920
Week 6141.304 ± 206.163147.409 ± 246.219252.328 ± 389.359
Week 12120.489 ± 211.56525.766 ± 233.860141.367 ± 213.926
SecondaryChange From Baseline in Procollagen Type 1 C-Terminal Propeptide Biomarker at Weeks 2, 4, 6 and 12

Blood and urine samples for analysis of cartilage, bone, angiogenesis, and inflammation biomarkers were collected. Procollagen type 1 C-terminal propeptide was analysed as a bone and cartilage biomarker.

Time frame:
Baseline, Weeks 2, 4, 6 and 12
Reported as:
Mean · mcg/L
Change From Baseline in Procollagen Type 1 C-Terminal Propeptide Biomarker at Weeks 2, 4, 6 and 12
mcg/LPalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Week 222.12 ± 61.97623.26 ± 11.58582.93 ± 109.010
Week 472.16 ± 98.69776.10 ± 110.041140.26 ± 155.036
Week 673.36 ± 130.43787.19 ± 96.451125.31 ± 110.389
Week 1251.21 ± 82.90147.30 ± 112.11396.49 ± 92.215
SecondaryChange From Baseline in Amount of Bone Formation (Volume) at Weeks 6 and 12

Low dose CT scan were used as a secondary imaging assessment of HO, and was performed at the same time points as plain radiographs. Interpretation of the CT scan documented the amount (volume) and grade of HO. The independent reviewer scored HO lesions according to the following scale for HO on CT. Grade 1 = fluid attenuation without evidence of calcification at CT, Grade 2 = calcification of soft tissues without evidence of bone formation, Grade 3 = immature bone formation, and Grade 4 = mature bone with cortical differentiation. Volume of new HO was determined according to the following steps: (1) calculate volume of new HO compared to baseline for each reviewer/HO ID, (2) sum the volume of new HO across HO IDs for each reviewer, and (3) average the volume of new HO across reviewers. Results from Primary Read reviews are presented.

Time frame:
Baseline, Weeks 6 and 12
Reported as:
Mean · cubic mm
Change From Baseline in Amount of Bone Formation (Volume) at Weeks 6 and 12
cubic mmPalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Week 62820.53 ± 11078.233326.58 ± 979.73311459.42 ± 29759.691
Week 123857.95 ± 11860.9781184.99 ± 3188.02016181.64 ± 41643.976
SecondaryPercentage of Subjects With Soft Tissue Swelling and Cartilage Formation Assessed by Magnetic Resonance Imaging (MRI) or Ultrasound (US) at Weeks 6 and 12

The MRI was utilized to evaluate the presence of soft tissue swelling/edema (and volume of the swelling/edema) and presence of cartilage formation (yes or no). For subjects who could not have an MRI, US was used to assess edema severity for the sub-set of subjects enrolled after this opinion was introduced in a protocol amendment. Imaging film from MRI was assessed by two independent readers. When there was sufficient agreement between the independent readers on volume, both of the independent readings were used for analysis with the volume measurements averaged. When there was insufficient agreement between the independent readers, an adjudication reading was provided and used for analysis. The US was used for soft tissue swelling/edema but not cartilage formation. Percentage calculated as % = 100 x n/N' where N' is the number of subjects with interpretable outcomes. Results from Primary Read reviews are presented.

Time frame:
Weeks 6 and 12
Reported as:
Number · percentage of subjects
Percentage of Subjects With Soft Tissue Swelling and Cartilage Formation Assessed by Magnetic Resonance Imaging (MRI) or Ultrasound (US) at Weeks 6 and 12
percentage of subjectsPalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Soft tissue swelling: Week 650.050.066.7
Soft tissue swelling: Week 1260.066.766.7
Cartilage formation: Week 615.40.00.0
Cartilage formation: Week 128.30.00.0
SecondaryChange From Baseline in Percent of Normal Arc of Motion at the Primary Joint (Flare-up Site) at Weeks 6 and 12

Active range of motion, expressed as the percent of normal arc of motion, measurements at the primary joint associated with the flare-up and adjoining joints was assessed by goniometer.

Time frame:
Baseline, Weeks 6 and 12
Reported as:
Mean · percent of normal arc of motion
Change From Baseline in Percent of Normal Arc of Motion at the Primary Joint (Flare-up Site) at Weeks 6 and 12
percent of normal arc of motionPalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Week 6-0.40 ± 9.574-1.36 ± 21.336-0.99 ± 18.951
Week 120.58 ± 15.079-4.23 ± 26.791-2.31 ± 18.963
SecondarySubject and Investigator Global Assessment of Movement at Weeks 6 and 12

Flare-up movement outcomes were independently assessed by both the subject (or parent of a subject under 8 years of age) and the Investigator at Weeks 6 and 12 by completing the global assessment of movement. The subject/parent completed the global assessment first. Prior to reviewing the subject's assessment, the Investigator completed his/her own assessment of the flare-up outcome. Subjects were assessed how the flare-up affected their movement on a scale ranging 1 to 5 where, 1 = severely worse movement and 5 = better movement compared with study Day 1 (day of first dose of study drug). Investigators were assessed how the flare-up affected the subject's movement on a scale ranging 1 to 5 where, 1 = severely worse movement and 5 = better movement compared with baseline (day of screening physical examination).

Time frame:
Weeks 6 and 12
Reported as:
Count of participants · Participants
Subject and Investigator Global Assessment of Movement at Weeks 6 and 12
ParticipantsPalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Subject Global Assessment: Week 6 — Score 1010
Subject Global Assessment: Week 6 — Score 2100
Subject Global Assessment: Week 6 — Score 3001
Subject Global Assessment: Week 6 — Score 4232
Subject Global Assessment: Week 6 — Score 5643
Subject Global Assessment: Week 12 — Score 1010
Subject Global Assessment: Week 12 — Score 2011
Subject Global Assessment: Week 12 — Score 3101
Subject Global Assessment: Week 12 — Score 4624
Subject Global Assessment: Week 12 — Score 5651
Investigator Global Assessment: Week 6 — Score 1110
Investigator Global Assessment: Week 6 — Score 2001
Investigator Global Assessment: Week 6 — Score 3001
Investigator Global Assessment: Week 6 — Score 4323
Investigator Global Assessment: Week 6 — Score 5551
Investigator Global Assessment: Week 12 — Score 1111
Investigator Global Assessment: Week 12 — Score 2010
Investigator Global Assessment: Week 12 — Score 3010
Investigator Global Assessment: Week 12 — Score 4824
Investigator Global Assessment: Week 12 — Score 5442
SecondaryChange From Baseline in Flare-Up Pain and Swelling at Weeks 2, 4, 6, 9 and 12

The pain and swelling associated with flare-ups was evaluated using 2 separate numeric rating scales, one for pain and one for swelling. The pain scale ranges from 0 to 10 where, 0 = no pain and 10 = worst pain ever experienced. The swelling scale ranges from 0 to 10 where, 0 = no swelling and 10 = worst swelling ever experienced. The Faces Pain Scale - Revised (FPS-R) was used for children less than 8 years old. The FPS-R ranges from 0 to 10 where, 0 = no pain and 10 = very much pain in two-point increments.

Time frame:
Baseline, Weeks 2, 4, 6, 9 and 12
Reported as:
Mean · units on a scale
Change From Baseline in Flare-Up Pain and Swelling at Weeks 2, 4, 6, 9 and 12
units on a scalePalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Flare-up pain: Week 2-2.5 ± 2.500.0 ± 2.40-2.0 ± 1.76
Flare-up pain: Week 4-3.2 ± 2.46-1.3 ± 1.58-1.9 ± 3.14
Flare-up pain: Week 6-3.5 ± 2.78-1.3 ± 1.58-2.4 ± 2.91
Flare-up pain: Week 9-3.8 ± 2.62-1.1 ± 1.64-2.1 ± 1.85
Flare-up pain: Week 12-3.6 ± 2.72-1.9 ± 2.42-2.2 ± 2.53
Flare-up swelling: Week 2-1.4 ± 2.76-1.3 ± 2.93-2.3 ± 2.79
Flare-up swelling: Week 4-1.7 ± 3.30-1.9 ± 1.81-2.0 ± 3.30
Flare-up swelling: Week 6-2.2 ± 3.32-2.0 ± 2.45-2.6 ± 3.50
Flare-up swelling: Week 9-2.7 ± 3.32-2.3 ± 2.43-1.9 ± 4.41
Flare-up swelling: Week 12-2.1 ± 3.73-2.5 ± 2.20-2.3 ± 3.16
SecondaryPercentage of Subjects Who Used Any Assistive Devices and Adaptations for Daily Living at Weeks 6 and 12

Subjects were given a list of FOP assistive devices and adaptations and asked to select those they use for daily living. The FOP assistive devices and adaptations included mobility aids, care attendants, eating tools, personal care tools/aids, bathroom aids and devices, bedroom aids and devices, home adaptations, work environment adaptations, technology adaptations, sports and recreation adaptations, school, and medical therapies for daily living.

Time frame:
Weeks 6 and 12
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Used Any Assistive Devices and Adaptations for Daily Living at Weeks 6 and 12
percentage of subjectsPalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Week 685.0100.0100.0
Week 1290.5100.0100.0
SecondaryDuration of Active Symptomatic Flare-up

The duration of active symptomatic flare-up was defined as the number of days the subject reported the presence of symptoms in the diary ('Is your flare-up ongoing today?') from Day 1 to study completion at Day 84. The mean number of days of active, symptomatic flare-up is presented for subjects with evaluable diary data.

Time frame:
From Day 1 to Day 84
Reported as:
Mean · days
Duration of Active Symptomatic Flare-up
daysPalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Duration of Active Symptomatic Flare-up22.1 ± 20.5344.1 ± 38.3634.4 ± 34.15
SecondaryChange From Baseline in Percentage of Worst Total Score for FOP-Specific Physical Function Questionnaire (FOP-PFQ) at Weeks 2, 4, 6, 9 and 12

The FOP-PFQ consists of 28 questions rated on scales from 1 to 5, with lower scores denoting more difficulty. The adult form of the FOP-PFQ was administered to subjects 15 years of age and older. There are two Pediatric FOP-PFQ (FOP-PFQ-P) forms: a self-completed form for 8 to 14 year-olds and a parent proxy-completed form for 5 to 14 year-olds. For subjects between 8 to 14 years of age, both the self-completed (for 8 to 14 year-olds) and the proxy-completed (for 5 to 14 year olds) forms of the FOP-PFQ-P were administered. However, only the proxy-completed form was used for analysis. Percentage of worst scores ranges from 0% to 100% with 0% = best possible function and 100% = worst possible function. Change from baseline for each time point is presented.

Time frame:
Baseline, Weeks 2, 4, 6, 9 and 12
Reported as:
Mean · units on a scale
Change From Baseline in Percentage of Worst Total Score for FOP-Specific Physical Function Questionnaire (FOP-PFQ) at Weeks 2, 4, 6, 9 and 12
units on a scalePalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Week 20.95 ± 5.4840.31 ± 3.8182.11 ± 6.659
Week 43.42 ± 7.9322.67 ± 7.2002.91 ± 8.427
Week 63.79 ± 7.7872.88 ± 7.5501.75 ± 5.980
Week 91.89 ± 5.432-0.52 ± 7.8814.91 ± 13.185
Week 124.22 ± 7.9151.08 ± 8.7243.02 ± 9.587
SecondaryChange From Baseline in Physical and Mental Health Using Age-Appropriate Forms of the Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale at Weeks 2, 4, 6, 9 and 12

The PROMIS Global Health contains 10 questions which are rated on scales from 1 to 5 or 0 to 10. Global physical health scores were calculated as the sum of scores from parameters 3, 6, 7, and 8 and ranges from 4 to 20 where, 4 = worse health and 20 = better health. Global mental health scores were calculated as the sum of scores from parameters 2, 4, 5, and 10 and ranges from 4 to 20 where, 4 = worse health and 20 = better health. For paediatric subjects, the PROMIS was administered as per the adult version. However, there is a single total score for the paediatric PROMIS (as opposed to global physical and global mental health scores as are in the adult version). The total score were converted to a T-score. A T-score of 50 is normal and increments of 10 are +/- 1 standard deviation away from the norm. A T-score \<50 indicates worse health, while a T-score \>50 indicates better health. The higher values (positive changes) indicate better health.

Time frame:
Baseline, Weeks 2, 4, 6, 9 and 12
Reported as:
Mean · t-score
Change From Baseline in Physical and Mental Health Using Age-Appropriate Forms of the Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale at Weeks 2, 4, 6, 9 and 12
t-scorePalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Adult-only: Global Physical Health T-Score: Week 22.76 ± 5.3080.00 ± 1.7685.90 ± 2.087
Adult-only: Global Physical Health T-Score: Week 44.66 ± 6.5902.66 ± 4.3455.56 ± 2.904
Adult-only: Global Physical Health T-Score: Week 64.69 ± 5.5857.08 ± 6.5915.73 ± 2.750
Adult-only: Global Physical Health T-Score: Week 94.96 ± 5.4895.58 ± 3.3814.94 ± 3.135
Adult-only:Global Physical Health T-Score: Week 123.97 ± 6.7644.98 ± 6.2463.78 ± 3.883
Adult-only: Global Mental Health T-Score: Week 23.66 ± 5.2163.20 ± 2.0241.98 ± 3.124
Adult-only: Global Mental Health T-Score: Week 43.32 ± 5.0662.28 ± 2.7007.30 ± 5.609
Adult-only: Global Mental Health T-Score: Week 64.15 ± 6.8782.54 ± 4.9804.34 ± 5.850
Adult-only: Global Mental Health T-Score: Week 94.62 ± 7.6841.68 ± 3.6415.38 ± 5.438
Adult-only: Global Mental Health T-Score: Week 124.33 ± 7.5273.10 ± 4.1271.04 ± 3.664
Paediatric-only: Global Health T-Score: Week 2-2.27 ± 4.2781.05 ± 2.352-1.80 ± 4.668
Paediatric-only: Global Health T-Score: Week 4-0.57 ± 2.4991.43 ± 6.352-6.40 ± 4.314
Paediatric-only: Global Health T-Score: Week 6-2.23 ± 3.4992.80 ± 4.955-3.30 ± 7.826
Paediatric-only: Global Health T-Score: Week 91.17 ± 2.0211.83 ± 1.434-3.50 ± 4.668
Paediatric-only: Global Health T-Score: Week 120.17 ± 7.572-2.13 ± 2.964-6.57 ± 1.950
SecondaryMaximum Measured Plasma Concentration (Cmax) of Palovarotene

The Cmax of palovarotene was determined.

Time frame:
Pre-dose and 3, 6, 10, and 24 hours (hrs) post-dose at Week 2, and at Week 4 or 6
Reported as:
Mean · picograms per milliliter (pg/mL)
Maximum Measured Plasma Concentration (Cmax) of Palovarotene
picograms per milliliter (pg/mL)Palovarotene 10/5 mgPalovarotene 5/2.5 mg
Week 295620.00 ± 30296.7735620.00 ± 19882.08
Week 4/Week 645505.88 ± 17061.0518958.57 ± 9238.62
SecondaryMinimum Measured Plasma Concentration (Cmin) of Palovarotene

The Cmin of palovarotene was determined.

Time frame:
Pre-dose and 3, 6, 10, and 24 hrs post-dose at Week 2, and at Week 4 or 6
Reported as:
Mean · pg/mL
Minimum Measured Plasma Concentration (Cmin) of Palovarotene
pg/mLPalovarotene 10/5 mgPalovarotene 5/2.5 mg
Week 23128.53 ± 2358.881739.40 ± 963.68
Week 4/Week 63879.00 ± 7042.29614.14 ± 289.72
SecondaryTime of Maximum Measured Plasma Concentration (Tmax) of Palovarotene

The Tmax obtained by inspection of palovarotene was determined.

Time frame:
Pre-dose and 3, 6, 10, and 24 hrs post-dose at Week 2, and at Week 4 or 6
Reported as:
Median · hr
Time of Maximum Measured Plasma Concentration (Tmax) of Palovarotene
hrPalovarotene 10/5 mgPalovarotene 5/2.5 mg
Week 23.00 (2.83 to 6.03)2.77 (2.08 to 5.88)
Week 4/Week 63.00 (2.75 to 6.00)3.00 (3.00 to 6.00)
SecondaryApparent Terminal Elimination Half-life (t1/2) of Palovarotene

The t1/2 was calculated as ln(2)/ λz. The number of data points included in the regression was determined by visual inspection, but a minimum of three data points in the terminal phase, excluding Cmax, was required to estimate λz.

Time frame:
Pre-dose and 3, 6, 10, and 24 hrs post-dose at Week 2, and at Week 4 or 6
Reported as:
Median · hr
Apparent Terminal Elimination Half-life (t1/2) of Palovarotene
hrPalovarotene 10/5 mgPalovarotene 5/2.5 mg
Week 24.33 (3.30 to 6.51)5.18 (3.29 to 5.94)
Week 4/Week 64.39 (3.11 to 6.38)4.40 (4.13 to 5.11)
SecondaryArea Under the Plasma Concentration Versus Time Curve Over the 24-hr Dosing Interval (AUC[0-24hr]) of Palovarotene

The AUC(0-24hr) was calculated using linear trapezoid rule.

Time frame:
Pre-dose and 3, 6, 10, and 24 hrs post-dose at Week 2, and at Week 4 or 6
Reported as:
Mean · hr*pg/mL
Area Under the Plasma Concentration Versus Time Curve Over the 24-hr Dosing Interval (AUC[0-24hr]) of Palovarotene
hr*pg/mLPalovarotene 10/5 mgPalovarotene 5/2.5 mg
Week 2686308.92 ± 246797.81350124.65 ± 181967.49
Week 4/Week 6311082.39 ± 128622.73142748.47 ± 84838.75
SecondaryApparent Clearance of Palovarotene (CL/F)

The CL/F was defined as dose/AUC0-24hr.

Time frame:
Pre-dose and 3, 6, 10, and 24 hrs post-dose at Week 2, and at Week 4 or 6
Reported as:
Mean · L/hr
Apparent Clearance of Palovarotene (CL/F)
L/hrPalovarotene 10/5 mgPalovarotene 5/2.5 mg
Week 215.55 ± 7.0312.84 ± 4.07
Week 4/Week 617.71 ± 7.4419.51 ± 10.66

Adverse events

Collected over From first dose of study drug (Day 1) up to and including the Week 12 visit, approximately 85 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Palovarotene 10/5 mg0/21 (0%)2/21 (9.5%)21/21 (100%)
Palovarotene 5/2.5 mg0/9 (0%)1/9 (11.1%)9/9 (100%)
Placebo0/10 (0%)1/10 (10%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventPalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Haemorrhagic ovarian cystReproductive system and breast disorders0/211/90/10
Asthmatic crisisRespiratory, thoracic and mediastinal disorders0/210/91/10
Condition aggravatedGeneral disorders2/210/90/10
MyoclonusNervous system disorders1/210/90/10
Most frequent other events
Showing 10 of 88
Most frequent other events
EventPalovarotene 10/5 mgPalovarotene 5/2.5 mgPlacebo
Dry skinSkin and subcutaneous tissue disorders17/215/93/10
Condition aggravatedGeneral disorders13/212/93/10
ArthralgiaMusculoskeletal and connective tissue disorders10/211/96/10
Lip dryGastrointestinal disorders7/215/91/10
HeadacheNervous system disorders8/211/93/10
PyrexiaGeneral disorders1/213/91/10
Pain in extremityMusculoskeletal and connective tissue disorders2/213/92/10
NauseaGastrointestinal disorders6/211/92/10
Chapped lipsGastrointestinal disorders5/210/92/10
HypoaesthesiaNervous system disorders0/212/92/10

Baseline characteristics

The safety population included all subjects who received at least 1 dose of study drug (placebo or palovarotene).

Age, Continuous
Age, Continuous(years)Palovarotene 10/5 mgPalovarotene 5/2.5 mgPlaceboTotal
Mean22.8 ± 10.317.9 ± 8.621.2 ± 13.721.3 ± 10.8
Age, Customized
Age, Customized(Participants)Palovarotene 10/5 mgPalovarotene 5/2.5 mgPlaceboTotal
Children (2-11 years)3429
Adolescents (12-17 years)5049
Adults (18-64 years)135422
Sex: Female, Male
Sex: Female, Male(Participants)Palovarotene 10/5 mgPalovarotene 5/2.5 mgPlaceboTotal
Female96722
Male123318
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Palovarotene 10/5 mgPalovarotene 5/2.5 mgPlaceboTotal
Hispanic or Latino2114
Not Hispanic or Latino138627
Unknown or Not Reported6039
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Palovarotene 10/5 mgPalovarotene 5/2.5 mgPlaceboTotal
White127625
Black or African American1102
Asian0011
Multiple2103
Not available6039
08

Study locations

4 sites
  • University of California San Francisco, Division of Endocrinology and Metabolism
    San Francisco, California 94143, United States
  • University of Pennsylvania, Center for Research in FOP & Related Disorders
    Philadelphia, Pennsylvania 19104, United States
  • Hôpital Necker-Enfants Malades, Department of Genetics
    Paris, France
  • The Royal National Orthopaedic Hospital, Brockley Hill
    Stanmore, Middlesex HA7 4LP, United Kingdom
09

References and documents

Publications

  • Shimono K, Tung WE, Macolino C, Chi AH, Didizian JH, Mundy C, Chandraratna RA, Mishina Y, Enomoto-Iwamoto M, Pacifici M, Iwamoto M. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists. Nat Med. 2011 Apr;17(4):454-60. doi: 10.1038/nm.2334. Epub 2011 Apr 3. Erratum In: Nat Med. 2012 Oct;18(10):1592. PubMed 21460849 ↗
  • Pignolo RJ, Baujat G, Hsiao EC, Keen R, Wilson A, Packman J, Strahs AL, Grogan DR, Kaplan FS. Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial. J Bone Miner Res. 2022 Oct;37(10):1891-1902. doi: 10.1002/jbmr.4655. Epub 2022 Aug 17. PubMed 35854638 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2014 to primary completion in May 2016, 22 months.

Results were first posted in Jun 2020, 4 years 1 month after primary completion. A results delay was requested in Oct 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2014
First posted
Jul 15, 2014
StartActual
Jul 14, 2014
Primary completionActual
May 23, 2016
CompletionActual
May 23, 2016
Results delay requested
Oct 20, 2017
Results first posted
Jun 24, 2020
Last update
Feb 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02190747
Responsible party
Sponsor
First posted
Jul 15, 2014
Start date
Jul 14, 2014
Primary completion
May 23, 2016
Completion
May 23, 2016
Results posted
Jun 24, 2020
Last update
Feb 16, 2021

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palovarotene

Start the discussion